Unless you combine with an anti-CD38 antibody... #EHA24RF #MMSM

Prochaine RCP nationale "MGCS: Gammapathie monoclonale de signification cutanée" organisée par notre centre constitutif intégré MaRIH avec le centre de ref AmyloseAL le 2/10/2024 à 17h, MP pour plus d'info Université Paris Cité Hôpital Saint-Louis AP-HP Société Française de Dermatologie Hématologie

Dr. Aurore Perrot presenting MIDAS trial. Incorporates MRD testing for the various pathways. MRD adapted consolidation and maintenance. Induction IsaKRD. Med age 59 yrs. #IMS24RF #mmsm

Real-world data in #MZL are rare and precious. So far: 🇺🇸 LEO Cohort Study, 🇮🇹NF10, 🇬🇧 HMRN Thanks to Lysa Lymphoma's REALYSA, we were able to build the first 🇫🇷 MZL prospective cohort. First results (2018-2021) are published today. More will come. onlinelibrary.wiley.com/doi/10.1002/ho…

Immune system one pager

🔥What's trending at #ASH24 in Marginal Zone Lymphoma (MZL)? Here's a quick breakdown of the key highlights. On the MZL abstracts agenda: • 3 translational • 3 clinical trials • 5 RWD Dive in to stay ahead! #ASH24 #MZL

Maladies rares, faire équipe ! Il reste des places pour la journée annuelle de la Plateforme d'expertise maladies rares Paris Nord sur les collaborations inter-centres experts 🗓️RDV le 13 décembre de 13h30 à 16h40 à Hôpital Robert-Debré AP-HP Assistance Publique – Hôpitaux de Paris (AP-HP) ou en ligne Infos bit.ly/40Bq9eA

Here are my Top 5 #ASH24 ASH myeloma abstracts. #ASH24VR Links to the full abstract. My Top 5 are based on new data, clinical impact, & methodology Thread with countdown👇

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

By request Our 2 hour ASH abstract session Aaron Goodman - “Papa Heme” Manni Mohyuddin and me and many others We get to the abstracts around 35 mins in So many good ones, including CAR PRISM and AQUILA #ASH24

Un test simple et rapide à faire pour ceux qui veulent prendre soins de leur santé par Institut national du cancer cancer.fr/actualites/mon…

Just published in the NEJM following Dr. Aurore Perrot 's presentation at #ASCO25 on behalf of the IFM group 🇫🇷 and C. Touzeau. 📢📄 MRD-driven strategy in NDMM, a major step forward for multiple myeloma research. #mmsm #MRD #NDMM #IFM

#ASCO25 And another one! Journal of Clinical Oncology: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc Nina Shah)

The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving them the comfort, control, and quality of life they truly deserve! ⁦Journal of Clinical Oncology⁩ ⁦IACH⁩ ⁦COMy⁩

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

📢 New publication in Clin Lymphoma Myeloma Leuk! Retreatment with anti-CD38-based combinations in multiple myeloma: real-world insights from the EMMY cohort study. ➡️ Real-life efficacy ➡️ Retreatment strategies ➡️ IFM collaboration 🔗 doi.org/10.1016/j.clml… #mmsm #AntiCD38

Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm nature.com/articles/s4157… European Hematology Association EMN Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics

Thanks Robert Z. Orlowski for highlighting our report of the first patient treated with anti-BCMA bispecific for R/R POEMS syndrome with a 20-year history in Haematologica Assistance Publique – Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis AP-HP MaRIH #POEMS #mmsm

Disparition du scientifique et immunologiste israélien Zelig Eshhar, pionnier de l’immunothérapie et considéré comme l'un des "pères" de la technologie des cellules CAR-T pour lutter contre les cancers, redonnant espoir à des milliers de patients dans le monde.

📢 New paper out in Ther Adv Hematol! 🧪 Real-world safety of venetoclax in hematologic malignancies using French pharmacovigilance data 🇫🇷 📖 doi.org/10.1177/204062… 👏 Huge thanks to Nicolas Gendron, David Smadja 🎗️🧡, Pierre-Edouard Debureaux, MD, PhD Student, and all the HEGP team for the key contribution!